Zelgen Biopharma's JAK3 Inhibitor ZL-82 Receives IND Approval for Atopic Dermatitis
Zenitar
Innovative Drug R&D and Industrialization Service Provider
▎Edited by the WuXi AppTec content team
Today (July 29), Zenitar announced that its self-developed Class 1 innovative drug ZL-82 tabletsFor the indication of atopic dermatitisThe clinical trial application has been approved.ZL-82 is a JAK3 inhibitor,This is its continuationRheumatoid Arthritis, Ulcerative ColitisAnother progress after the approval of clinical indications.
Atopic dermatitis is a chronic inflammatory skin disease accompanied by severe itching. As aNon-fatal skin diseases,Whether globally or in China,The prevalence of atopic dermatitis is high.The disease burden is heavy. Epidemiological studies show that globallyAtopic DermatitisAt least 230 million patients in ChinaAtopic DermatitisThe age-standardized prevalence rate is 2.5%, and the clinical needs have not been met.
According to the public information from Zenitar,ZL-82 is a highly selective covalent irreversible inhibitor targeting non-receptor tyrosine protein kinase 3 (JAK3).Preclinical studies show that ZL-82 has high selectivity, excellent pharmacokinetic (PK) properties, and "best-in-class" potential in terms of safety and efficacy.
ZenitarZenitar is a biotechnology company affiliated with the State Key Laboratory of Biotherapy at West China Hospital, Sichuan University.Founded by Professor Chen LijuanFocusing on malignant tumors, inflammation, and autoimmune diseases, the company is committed to discovering, developing, and commercializing innovative drugs that are potentially "first-in-class" and "best-in-class."2024November,Zenitar Announces CompletionByChengdu Sci-Tech Investment Management's Precision Medicine Industry Innovation FundLeading the investmentSeries B Financing, toAdvance the Phase 2/3 clinical development of the company's two products and accelerate the research of core technologies and other pipelines.
Zenitar R&D Pipeline (Source: Zenitar Official Website)
[1] Zenitar Completes Series B Financing, Accelerating Clinical Development of Core Pipeline. Retrieved Nov 24, 2023, from https://mp.weixin.qq.com/s/MHwUHrl4qCrfmbZyCvIi5w
[2] Good News | ZL-82 Tablets for Atopic Dermatitis Receive Clinical Approval.Retrieved Jul 29，2024, from http://www.zenitar.com.cn/index.php/2024/07/29/54274/
This article was compiled and edited by the WuXi AppTec content team based on publicly available information. Feel free to share it on your personal social media feeds. For reprint authorization or other collaboration inquiries, please contact wuxi_media@wuxiapptec.com.
Disclaimer: The content team of WuXi AppTec focuses on introducing the research progress in global biopharmaceuticals and health. This article is for information exchange purposes only, and the views expressed in the article do not represent the position of WuXi AppTec, nor does it imply that WuXi AppTec supports or opposes these views. This article is not a recommendation for treatment plans. For guidance on treatment options, please visit a正规 hospital.
